Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Preferred Drug List NEW DRUG REVIEW Proprietary Name: Alimta® Common Name: Pemetrexed disodium PDL Category: Antineoplastic Comparable Products Preferred Drug List/ Recommended Drug List Status Summary Indications and Usage: In combination with cisplatin for the treatment of patients with malignant pleural mesothelioma (MPM) whose disease is unresectable or who are otherwise not candidates for curative surgery. Dosage Forms: Powder for injection, lyophilized: 500 mg. In single-use vials. Recommended Dosage: Malignant pleural mesothelioma (MPM): The recommended dose of pemetrexed is 500 mg/m 2 administered as an IV infusion over 10 minutes on day 1 of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m 2 infused over 2 hours beginning approximately 30 minutes after the end of pemetrexed administration. Non-small cell lung cancer (NSCLC): The recommended dose of pemetrexed is 500 mg/m 2 administered as an IV infusion over 10 minutes on day 1 of each 21-day cycle Common Adverse Drug Reactions: Neutropenia, leukopenia, anemia, thrombocytopenia, fatigue, fever, infection, stomatitis/pharyngitis and rash/desquamation. Contraindications: History of severe hypersensitivity reaction to pemetrexed or any other ingredient used in the formulation. Manufacturer: Eli Lilly Analysis: Alimta® is the first drug to be approved by the Food and Drug Administration (FDA) for the treatment of malignant pleural mesothelioma (cancer of the inside lining of the chest cavity usually caused by asbestos exposure) when surgery is not an option. Alimta® is an orphan drug and is to be used in combination with cisplatin. In clinical trials, patients who were treated with Alimta® and cisplatin had a median survival rate of 12.1 months compared to 9.3 months for patients treated with cisplatin alone. Preferred Drug Recommended Drug IME Recommendation: Non-Preferred Drug Preferred Drug with Conditions Prepared By: Iowa Medicaid Enterprise Non-Recommended Drug Date: 8/12/2017